Gilead Sciences (NASDAQ: GILD) has collected three U.S. drug approvals since May. Its own full-year guidance still implies that product sales growth will roughly halve in the second half of the year. That is not a contradiction. It is what happens when approvals land in small markets — or in a market the company already owns.
The approval count is the part the wires carried. It is also the part that tells a fund manager the least. An approval from the FDA, the U.S. drug regulator, is permission to sell. It is not demand, and it is not price. The narrower question is which of the three actually moves the revenue line.
What was approved
- May 22 — Hepcludex (bulevirtide-gmod), for chronic hepatitis delta virus infection in adults. Gilead's release calls it the first treatment for the disease approved in the United States.
- June 24 — Trodelvy (sacituzumab govitecan-hziy), as a first-line treatment for metastatic triple-negative breast cancer. The FDA's approval notice cleared it both on its own and alongside Keytruda, Merck's immunotherapy.
- Aug. 27 — Bixlenvo, a single daily tablet combining bictegravir with lenacapavir, for adults with HIV who already have the virus under control.
Three approvals in 97 days is a dense run of regulatory news. The trouble with a count is that it treats them as equals. They are not close to equal.
Why it matters
An approval count is the cheapest possible summary of a drugmaker. It is easy to publish and easy to read. It also flattens the one distinction that decides whether regulatory news ever reaches the revenue line — whether a drug opens a market or defends one.
Gilead's three approvals split cleanly on that test. One treats a disease that had no approved therapy at all, in a population small enough to count. One moves an existing cancer drug earlier in the course of treatment, which genuinely widens the pool of patients who qualify. The third offers a new tablet to people already taking a Gilead tablet.
That last category is where most of the company's mass sits. Readers are being handed a tally when the useful question is about mix. Gilead's own guidance, published in early August, already answers it.
The number the guidance already contains
Gilead raised its full-year product sales guidance on Aug. 4. The raise was real, and it was small. Set the new range against what the company had already sold this year, and the second half does the rest of the arithmetic by itself.
| Product sales | 2025 actual | 2026 | Change |
|---|---|---|---|
| First half | $13,668M | $14,574M | +6.6% |
| Second half | $15,247M | $15,526M–$15,826M (implied) | +1.8% to +3.8% |
| Full year | $28,915M | $30,100M–$30,400M (guided) | +4.1% to +5.1% |
First-half figures come from Gilead's second-quarter Form 10-Q. The full-year actual is from the company's fourth-quarter earnings release. The second-half row is not published by Gilead — it is the guidance range minus the first half, with the prior year derived the same way.
So the company grew through June at a pace its own range says will not continue. Even the top of the guidance leaves the back half growing at little more than half the speed of the front. That figure was published more than three weeks before the most recent approval, and it has sat underneath the approval headlines ever since.
A guidance range is not a neutral forecast. It is a number management chooses, and management teams generally set ranges they expect to clear. That is what makes the implied second half worth reading rather than alarming. The company is telling the market what it feels sure of, and it feels less sure about the back half than the front half actually delivered.
The obvious objection, and what survives it
One product explains a good deal of that. Veklury, Gilead's COVID-19 antiviral, sold $911 million in 2025, according to the company's fourth-quarter release. Gilead's August guidance puts it near $160 million this year. A shrinking pandemic drug drags on the total in a way that says nothing at all about the new approvals.
Strip it out and the slowdown softens. It does not disappear.
| Excluding Veklury | 2025 | 2026 | Change |
|---|---|---|---|
| Second quarter | $6,926M | $7,604M | +9.8% |
| Full year | $28,004M | $29,940M–$30,240M (guided) | +6.9% to +8.0% |
In other words, the company grew close to ten percent last quarter without the COVID drug, and is guiding to roughly seven for the year without it. The direction of travel is the same whichever way the numbers are cut. Something in the second half is expected to be slower than the first, and the guidance was written by the people who know the launch plans.
Why the biggest approval is a defensive one
Biktarvy sold $3,772 million in the second quarter, against total product sales of $7,627 million. Both figures come from Gilead's second-quarter Form 10-Q, and the division between them is ours. It works out to 49.5%. One pill carries almost exactly half the company. Bixlenvo is built to sit in the same place. Its two pivotal trials, ARTISTRY-1 and ARTISTRY-2, enrolled patients switching from complex multi-tablet regimens and from Biktarvy itself, according to Gilead's approval release.
A switch drug is not worthless — far from it. Moving patients onto a newer combination shifts the franchise onto a later-expiring patent. It also gives Gilead an answer for people who cannot tolerate what they take now. But revenue that arrives by moving a patient from one Gilead tablet to another Gilead tablet is not the same as revenue from a new patient. The first defends a position. The second grows one.
Switching in HIV is slow by nature. Patients whose virus is suppressed and who tolerate their regimen have little reason to change anything. Physicians are cautious about disturbing what already works. Uptake for a switch product tends to build across years rather than quarters. That alone is a reason a late-August approval was never going to rescue a second-half number.
Where the growth actually came from
Quarterly product figures in this section come from Gilead's second-quarter Form 10-Q; the year-on-year differences are ours.
Trodelvy sold $457 million in the quarter, up from $364 million. The first-line approval matters here in a way it does not for the others. Moving earlier in the treatment sequence enlarges the pool of eligible patients rather than deepening a pool the company already serves.
The rest of the portfolio is worth laying out plainly. HIV product sales rose $605 million in the quarter. Total product sales rose $573 million. Everything outside HIV therefore shrank by $32 million.
Veklury accounts for that gap and more, having lost $105 million. Net of the COVID drug, the whole non-HIV portfolio added $73 million. Trodelvy on its own added $93 million. Cell therapy, liver disease and everything else in that group therefore contracted by roughly $20 million combined.
This is the connection an approval count obscures. Gilead is an HIV company trying to become something broader, and in the most recent quarter the broadening consisted of a single drug.
That is the shape of a business with one enormous franchise and a set of much smaller ones. It is not a criticism. It is the reason a tally of approvals cannot stand in for a look at where the money actually sits. A drugmaker with half its sales in one pill will always find that pill louder than anything else on the page.
Hepcludex: first of its kind, and small
Hepatitis delta is a severe co-infection that only affects people already carrying hepatitis B. Gilead's release estimates 40,000 to 80,000 people in the United States have it. That is a genuine unmet need and a real medical first. It is also a population counted in tens of thousands, set against an HIV business counted in millions of prescriptions.
Being first in a disease is worth something beyond the immediate sales line. It sets the standard of care, and it hands the company the reference arm for every trial that follows. But a first-in-disease approval in a rare condition is a scientific and reputational event more than a financial one, at least in its opening years.
The approval also carries a condition. Accelerated approval means the FDA cleared the drug on a laboratory marker — here, reduced virus levels and normalized liver enzymes — rather than on proof that patients live longer or better. Gilead has committed to a long-term outcomes study, which it says has already begun. Clearance of this kind can be withdrawn if the confirmatory work disappoints.
The timing has precedent worth remembering. The FDA rejected this same drug in October 2022. Gilead's statement at the time said the complete response letter concerned the manufacture and delivery of the drug, not its safety or efficacy. Approval followed roughly three and a half years later.
What LineVest wrote last month, and what changed
LineVest covered Gilead's second quarter on Aug. 21, when an $11.2 billion charge for acquired research turned the period into a $9.0 billion net loss. That charge paid for Arcellx, Tubulis and Ouro Medicines — three biotechs whose lead programs are still in trials. We framed the loss as an accounting outcome rather than a demand problem, and it was.
Here is what the approval run adds to that picture. None of the three approvals came from those purchases. Hepcludex came from MYR GmbH, a German hepatitis specialist Gilead acquired in December 2020 for approximately $1.4 billion. Trodelvy came from Immunomedics, the cancer biotech Gilead bought in 2020 for $21 billion. Bixlenvo came out of Gilead's own laboratories.
The current run of approvals is therefore a report card on the earlier deal vintage, not on this year's. And that report card has a number attached. Immunomedics cost $21 billion; Trodelvy sold $1,397 million across all of last year, about 6.7% of the purchase price in annual revenue.
Cancer drugs take longer to earn out than antivirals, because each new indication requires a separate multi-year clinical program and its own regulatory review. Trodelvy launched commercially in 2020. At six years and roughly $1.4 billion in annual revenue, that is about 6.7 cents on every dollar Gilead paid for Immunomedics in a single year's sales. That number will grow — and the first-line triple-negative breast cancer label is the clearest reason to think it accelerates from here. But the deal was always a long-dated bet, and it is still in its early chapters. That is the context that belongs beside any approval headline.
This article is based on public disclosures including Gilead Sciences' second-quarter Form 10-Q, fourth-quarter earnings release, and August 4, 2026 guidance update, as well as FDA approval notices and Gilead press releases. It is provided for informational purposes only and does not constitute investment advice. LineVest News is not a registered investment adviser.
